Protonix Delayed-Release (PANTOPRAZOLE SODIUM)
Protonix Delayed-Release (PANTOPRAZOLE SODIUM) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Protonix Delayed-Release; Generic name: PANTOPRAZOLE SODIUM; Manufacturer: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc..
| Brand name | Protonix Delayed-Release |
|---|---|
| Generic name | PANTOPRAZOLE SODIUM |
| Manufacturer | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. |
| Used for | 1 INDICATIONS AND USAGE PROTONIX For Delayed-Release Oral Suspension and PROTONIX Delayed-Release Tablets are indicated for: PROTONIX is a proton pump inhibitor (PPI) indicated for the following: • Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) • Maintenance of Healing of Erosive Esophagitis ( 1.2 ) • Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( 1.3 ) 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) PROTONIX is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing an |
| Dosage | 2 DOSAGE AND ADMINISTRATION Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD ( 2.1 ) Adults 40 mg Once Daily for up to 8 wks Children (5 years and older) ≥ 15 kg to < 40 kg 20 mg Once Daily for up to 8 wks ≥ 40 kg 40 mg Maintenance of Healing of Erosive Esophagitis ( 2.1 ) Adults 40 mg Once Daily Controlled studies did not extend beyond 12 months Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome ( 2.1 ) Adults 40 mg Twice Daily |
| Active ingredient(s) | PANTOPRAZOLE SODIUM |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08098cb2-c048-4640-f387-6beec4a38936 |